Amylyx Pharmaceuticals, Inc. (AMLX) company profile

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for endocrine disorders and neurodegenerative diseases. Its pipeline includes avexitide, an investigational glucagon-like peptide-1 receptor antagonist undergoing evaluation for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also advances AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for metabolic and rare conditions. Because its drug candidates remain in clinical and preclinical development, the company currently serves patient populations and study participants affected by these underserved medical conditions rather than commercial consumers.

The company conducts clinical trials across multiple medical centers, including twenty-one study sites in the United States for its lead trial. Its research initiatives, academic partnerships, and patent rights span international jurisdictions, including the United States, Canada, and Europe. Amylyx contracts external manufacturing organizations for the clinical production and packaging of its investigational products. The provided text does not identify the location of the company's corporate headquarters.

Summary of the business section of Amylyx Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price per share is $19.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 136 full-time employees.”